Hypertension after kidney donation: Incidence, predictors, and correlates

Research output: Contribution to journalArticle

Otto A. Sanchez, Laine K. Ferrara, Sarah Rein, Danielle Berglund, Arthur J. Matas, Hassan N. Ibrahim

Incidence of postdonation hypertension, risk factors associated with its development, and impact of type of treatment received on renal outcomes were determined in 3700 kidney donors. Using Cox proportional hazard model, adjusted hazard ratios (HRs) for cardiovascular disease (CVD); estimated glomerular filtration rate (eGFR) <60, <45, <30 mL/min/1.73m2; end stage renal disease (ESRD); and death in hypertensive donors were determined. After a mean (standard deviation [SD]) of 16.6 (11.9) years of follow-up, 1126 (26.8%) donors developed hypertension and 894 with known antihypertensive medications. Hypertension developed in 4%, 10%, and 51% at 5, 10, and 40 years, respectively, and was associated with proteinuria, eGFR < 30, 45, and 60 mL/min/1.73m2, CVD, and death. Blood pressure was <140/90 mm Hg at last follow-up in 75% of hypertensive donors. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (compared to other antihypertensive agents) was associated with a lower risk for eGFR <45 mL/min/1.73m², HR 0.64 (95% confidence interval [CI] 0.45-0.9), P =.01, and also less ESRD; HR 0.03 (95% CI 0.001-0.20), P =.004. In this predominantly Caucasian cohort, hypertension is common after donation, well controlled in most donors, and factors associated with its development are similar to those in the general population.

Original languageEnglish (US)
Pages (from-to)2534-2543
Number of pages10
JournalAmerican Journal of Transplantation
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2018

PMID: 29498216

Altmetrics

Cite this

Standard

Hypertension after kidney donation : Incidence, predictors, and correlates. / Sanchez, Otto A.; Ferrara, Laine K.; Rein, Sarah; Berglund, Danielle; Matas, Arthur J.; Ibrahim, Hassan N.

In: American Journal of Transplantation, Vol. 18, No. 10, 01.10.2018, p. 2534-2543.

Research output: Contribution to journalArticle

Harvard

Sanchez, OA, Ferrara, LK, Rein, S, Berglund, D, Matas, AJ & Ibrahim, HN 2018, 'Hypertension after kidney donation: Incidence, predictors, and correlates' American Journal of Transplantation, vol. 18, no. 10, pp. 2534-2543. https://doi.org/10.1111/ajt.14713

APA

Sanchez, O. A., Ferrara, L. K., Rein, S., Berglund, D., Matas, A. J., & Ibrahim, H. N. (2018). Hypertension after kidney donation: Incidence, predictors, and correlates. American Journal of Transplantation, 18(10), 2534-2543. https://doi.org/10.1111/ajt.14713

Vancouver

Sanchez OA, Ferrara LK, Rein S, Berglund D, Matas AJ, Ibrahim HN. Hypertension after kidney donation: Incidence, predictors, and correlates. American Journal of Transplantation. 2018 Oct 1;18(10):2534-2543. https://doi.org/10.1111/ajt.14713

Author

Sanchez, Otto A. ; Ferrara, Laine K. ; Rein, Sarah ; Berglund, Danielle ; Matas, Arthur J. ; Ibrahim, Hassan N. / Hypertension after kidney donation : Incidence, predictors, and correlates. In: American Journal of Transplantation. 2018 ; Vol. 18, No. 10. pp. 2534-2543.

BibTeX

@article{b6e8eb7221fa4a69abb0e8ba382bf420,
title = "Hypertension after kidney donation: Incidence, predictors, and correlates",
abstract = "Incidence of postdonation hypertension, risk factors associated with its development, and impact of type of treatment received on renal outcomes were determined in 3700 kidney donors. Using Cox proportional hazard model, adjusted hazard ratios (HRs) for cardiovascular disease (CVD); estimated glomerular filtration rate (eGFR) <60, <45, <30 mL/min/1.73m2; end stage renal disease (ESRD); and death in hypertensive donors were determined. After a mean (standard deviation [SD]) of 16.6 (11.9) years of follow-up, 1126 (26.8{\%}) donors developed hypertension and 894 with known antihypertensive medications. Hypertension developed in 4{\%}, 10{\%}, and 51{\%} at 5, 10, and 40 years, respectively, and was associated with proteinuria, eGFR < 30, 45, and 60 mL/min/1.73m2, CVD, and death. Blood pressure was <140/90 mm Hg at last follow-up in 75{\%} of hypertensive donors. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (compared to other antihypertensive agents) was associated with a lower risk for eGFR <45 mL/min/1.73m², HR 0.64 (95{\%} confidence interval [CI] 0.45-0.9), P =.01, and also less ESRD; HR 0.03 (95{\%} CI 0.001-0.20), P =.004. In this predominantly Caucasian cohort, hypertension is common after donation, well controlled in most donors, and factors associated with its development are similar to those in the general population.",
keywords = "clinical research/practice, donors and donation: donor follow-up, epidemiology, hypertension/antihypertensives, kidney transplantation/nephrology",
author = "Sanchez, {Otto A.} and Ferrara, {Laine K.} and Sarah Rein and Danielle Berglund and Matas, {Arthur J.} and Ibrahim, {Hassan N.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/ajt.14713",
language = "English (US)",
volume = "18",
pages = "2534--2543",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley",
number = "10",

}

RIS

TY - JOUR

T1 - Hypertension after kidney donation

T2 - American Journal of Transplantation

AU - Sanchez, Otto A.

AU - Ferrara, Laine K.

AU - Rein, Sarah

AU - Berglund, Danielle

AU - Matas, Arthur J.

AU - Ibrahim, Hassan N.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Incidence of postdonation hypertension, risk factors associated with its development, and impact of type of treatment received on renal outcomes were determined in 3700 kidney donors. Using Cox proportional hazard model, adjusted hazard ratios (HRs) for cardiovascular disease (CVD); estimated glomerular filtration rate (eGFR) <60, <45, <30 mL/min/1.73m2; end stage renal disease (ESRD); and death in hypertensive donors were determined. After a mean (standard deviation [SD]) of 16.6 (11.9) years of follow-up, 1126 (26.8%) donors developed hypertension and 894 with known antihypertensive medications. Hypertension developed in 4%, 10%, and 51% at 5, 10, and 40 years, respectively, and was associated with proteinuria, eGFR < 30, 45, and 60 mL/min/1.73m2, CVD, and death. Blood pressure was <140/90 mm Hg at last follow-up in 75% of hypertensive donors. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (compared to other antihypertensive agents) was associated with a lower risk for eGFR <45 mL/min/1.73m², HR 0.64 (95% confidence interval [CI] 0.45-0.9), P =.01, and also less ESRD; HR 0.03 (95% CI 0.001-0.20), P =.004. In this predominantly Caucasian cohort, hypertension is common after donation, well controlled in most donors, and factors associated with its development are similar to those in the general population.

AB - Incidence of postdonation hypertension, risk factors associated with its development, and impact of type of treatment received on renal outcomes were determined in 3700 kidney donors. Using Cox proportional hazard model, adjusted hazard ratios (HRs) for cardiovascular disease (CVD); estimated glomerular filtration rate (eGFR) <60, <45, <30 mL/min/1.73m2; end stage renal disease (ESRD); and death in hypertensive donors were determined. After a mean (standard deviation [SD]) of 16.6 (11.9) years of follow-up, 1126 (26.8%) donors developed hypertension and 894 with known antihypertensive medications. Hypertension developed in 4%, 10%, and 51% at 5, 10, and 40 years, respectively, and was associated with proteinuria, eGFR < 30, 45, and 60 mL/min/1.73m2, CVD, and death. Blood pressure was <140/90 mm Hg at last follow-up in 75% of hypertensive donors. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (compared to other antihypertensive agents) was associated with a lower risk for eGFR <45 mL/min/1.73m², HR 0.64 (95% confidence interval [CI] 0.45-0.9), P =.01, and also less ESRD; HR 0.03 (95% CI 0.001-0.20), P =.004. In this predominantly Caucasian cohort, hypertension is common after donation, well controlled in most donors, and factors associated with its development are similar to those in the general population.

KW - clinical research/practice

KW - donors and donation: donor follow-up

KW - epidemiology

KW - hypertension/antihypertensives

KW - kidney transplantation/nephrology

UR - http://www.scopus.com/inward/record.url?scp=85044863943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044863943&partnerID=8YFLogxK

U2 - 10.1111/ajt.14713

DO - 10.1111/ajt.14713

M3 - Article

VL - 18

SP - 2534

EP - 2543

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 10

ER -

ID: 50498493